Global CD38 Monoclonal Antibody Drugs Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “CD38 Monoclonal Antibody Drugs Industry Forecast” looks at past sales and reviews total world CD38 Monoclonal Antibody Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected CD38 Monoclonal Antibody Drugs sales for 2023 through 2029. With CD38 Monoclonal Antibody Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD38 Monoclonal Antibody Drugs industry.
This Insight Report provides a comprehensive analysis of the global CD38 Monoclonal Antibody Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CD38 Monoclonal Antibody Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global CD38 Monoclonal Antibody Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD38 Monoclonal Antibody Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD38 Monoclonal Antibody Drugs.
The global CD38 Monoclonal Antibody Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CD38 Monoclonal Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CD38 Monoclonal Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CD38 Monoclonal Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CD38 Monoclonal Antibody Drugs players cover Johnson, Sanofi, Takeda Pharmaceutical Company, CASI Pharmaceutical Company and Mab Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CD38 Monoclonal Antibody Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global CD38 Monoclonal Antibody Drugs market?
What factors are driving CD38 Monoclonal Antibody Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do CD38 Monoclonal Antibody Drugs market opportunities vary by end market size?
How does CD38 Monoclonal Antibody Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “CD38 Monoclonal Antibody Drugs Industry Forecast” looks at past sales and reviews total world CD38 Monoclonal Antibody Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected CD38 Monoclonal Antibody Drugs sales for 2023 through 2029. With CD38 Monoclonal Antibody Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CD38 Monoclonal Antibody Drugs industry.
This Insight Report provides a comprehensive analysis of the global CD38 Monoclonal Antibody Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CD38 Monoclonal Antibody Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global CD38 Monoclonal Antibody Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD38 Monoclonal Antibody Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CD38 Monoclonal Antibody Drugs.
The global CD38 Monoclonal Antibody Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CD38 Monoclonal Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CD38 Monoclonal Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CD38 Monoclonal Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CD38 Monoclonal Antibody Drugs players cover Johnson, Sanofi, Takeda Pharmaceutical Company, CASI Pharmaceutical Company and Mab Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CD38 Monoclonal Antibody Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Daretuzumab
- Isartuximab
- Engineered Toxin Body
- Multiple Myeloma
- Diffuse Large B Cell Lymphoma
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Johnson
- Sanofi
- Takeda Pharmaceutical Company
- CASI Pharmaceutical Company
- Mab Biopharma
What is the 10-year outlook for the global CD38 Monoclonal Antibody Drugs market?
What factors are driving CD38 Monoclonal Antibody Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do CD38 Monoclonal Antibody Drugs market opportunities vary by end market size?
How does CD38 Monoclonal Antibody Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CD38 Monoclonal Antibody Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for CD38 Monoclonal Antibody Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for CD38 Monoclonal Antibody Drugs by Country/Region, 2018, 2022 & 2029
2.2 CD38 Monoclonal Antibody Drugs Segment by Type
2.2.1 Daretuzumab
2.2.2 Isartuximab
2.2.3 Engineered Toxin Body
2.3 CD38 Monoclonal Antibody Drugs Sales by Type
2.3.1 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global CD38 Monoclonal Antibody Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Type (2018-2023)
2.4 CD38 Monoclonal Antibody Drugs Segment by Application
2.4.1 Multiple Myeloma
2.4.2 Diffuse Large B Cell Lymphoma
2.4.3 Other
2.5 CD38 Monoclonal Antibody Drugs Sales by Application
2.5.1 Global CD38 Monoclonal Antibody Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global CD38 Monoclonal Antibody Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Application (2018-2023)
3 GLOBAL CD38 MONOCLONAL ANTIBODY DRUGS BY COMPANY
3.1 Global CD38 Monoclonal Antibody Drugs Breakdown Data by Company
3.1.1 Global CD38 Monoclonal Antibody Drugs Annual Sales by Company (2018-2023)
3.1.2 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company (2018-2023)
3.2 Global CD38 Monoclonal Antibody Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global CD38 Monoclonal Antibody Drugs Revenue by Company (2018-2023)
3.2.2 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company (2018-2023)
3.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Company
3.4 Key Manufacturers CD38 Monoclonal Antibody Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD38 Monoclonal Antibody Drugs Product Location Distribution
3.4.2 Players CD38 Monoclonal Antibody Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR CD38 MONOCLONAL ANTIBODY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic CD38 Monoclonal Antibody Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global CD38 Monoclonal Antibody Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global CD38 Monoclonal Antibody Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic CD38 Monoclonal Antibody Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global CD38 Monoclonal Antibody Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global CD38 Monoclonal Antibody Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas CD38 Monoclonal Antibody Drugs Sales Growth
4.4 APAC CD38 Monoclonal Antibody Drugs Sales Growth
4.5 Europe CD38 Monoclonal Antibody Drugs Sales Growth
4.6 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Growth
5 AMERICAS
5.1 Americas CD38 Monoclonal Antibody Drugs Sales by Country
5.1.1 Americas CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023)
5.1.2 Americas CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023)
5.2 Americas CD38 Monoclonal Antibody Drugs Sales by Type
5.3 Americas CD38 Monoclonal Antibody Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD38 Monoclonal Antibody Drugs Sales by Region
6.1.1 APAC CD38 Monoclonal Antibody Drugs Sales by Region (2018-2023)
6.1.2 APAC CD38 Monoclonal Antibody Drugs Revenue by Region (2018-2023)
6.2 APAC CD38 Monoclonal Antibody Drugs Sales by Type
6.3 APAC CD38 Monoclonal Antibody Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe CD38 Monoclonal Antibody Drugs by Country
7.1.1 Europe CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023)
7.1.2 Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023)
7.2 Europe CD38 Monoclonal Antibody Drugs Sales by Type
7.3 Europe CD38 Monoclonal Antibody Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CD38 Monoclonal Antibody Drugs by Country
8.1.1 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type
8.3 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CD38 Monoclonal Antibody Drugs
10.3 Manufacturing Process Analysis of CD38 Monoclonal Antibody Drugs
10.4 Industry Chain Structure of CD38 Monoclonal Antibody Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CD38 Monoclonal Antibody Drugs Distributors
11.3 CD38 Monoclonal Antibody Drugs Customer
12 WORLD FORECAST REVIEW FOR CD38 MONOCLONAL ANTIBODY DRUGS BY GEOGRAPHIC REGION
12.1 Global CD38 Monoclonal Antibody Drugs Market Size Forecast by Region
12.1.1 Global CD38 Monoclonal Antibody Drugs Forecast by Region (2024-2029)
12.1.2 Global CD38 Monoclonal Antibody Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CD38 Monoclonal Antibody Drugs Forecast by Type
12.7 Global CD38 Monoclonal Antibody Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Johnson
13.1.1 Johnson Company Information
13.1.2 Johnson CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.1.3 Johnson CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Johnson Main Business Overview
13.1.5 Johnson Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.2.3 Sanofi CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Takeda Pharmaceutical Company
13.3.1 Takeda Pharmaceutical Company Company Information
13.3.2 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.3.3 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Takeda Pharmaceutical Company Main Business Overview
13.3.5 Takeda Pharmaceutical Company Latest Developments
13.4 CASI Pharmaceutical Company
13.4.1 CASI Pharmaceutical Company Company Information
13.4.2 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.4.3 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 CASI Pharmaceutical Company Main Business Overview
13.4.5 CASI Pharmaceutical Company Latest Developments
13.5 Mab Biopharma
13.5.1 Mab Biopharma Company Information
13.5.2 Mab Biopharma CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.5.3 Mab Biopharma CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Mab Biopharma Main Business Overview
13.5.5 Mab Biopharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CD38 Monoclonal Antibody Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for CD38 Monoclonal Antibody Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for CD38 Monoclonal Antibody Drugs by Country/Region, 2018, 2022 & 2029
2.2 CD38 Monoclonal Antibody Drugs Segment by Type
2.2.1 Daretuzumab
2.2.2 Isartuximab
2.2.3 Engineered Toxin Body
2.3 CD38 Monoclonal Antibody Drugs Sales by Type
2.3.1 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global CD38 Monoclonal Antibody Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Type (2018-2023)
2.4 CD38 Monoclonal Antibody Drugs Segment by Application
2.4.1 Multiple Myeloma
2.4.2 Diffuse Large B Cell Lymphoma
2.4.3 Other
2.5 CD38 Monoclonal Antibody Drugs Sales by Application
2.5.1 Global CD38 Monoclonal Antibody Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global CD38 Monoclonal Antibody Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Application (2018-2023)
3 GLOBAL CD38 MONOCLONAL ANTIBODY DRUGS BY COMPANY
3.1 Global CD38 Monoclonal Antibody Drugs Breakdown Data by Company
3.1.1 Global CD38 Monoclonal Antibody Drugs Annual Sales by Company (2018-2023)
3.1.2 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company (2018-2023)
3.2 Global CD38 Monoclonal Antibody Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global CD38 Monoclonal Antibody Drugs Revenue by Company (2018-2023)
3.2.2 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company (2018-2023)
3.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Company
3.4 Key Manufacturers CD38 Monoclonal Antibody Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD38 Monoclonal Antibody Drugs Product Location Distribution
3.4.2 Players CD38 Monoclonal Antibody Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR CD38 MONOCLONAL ANTIBODY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic CD38 Monoclonal Antibody Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global CD38 Monoclonal Antibody Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global CD38 Monoclonal Antibody Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic CD38 Monoclonal Antibody Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global CD38 Monoclonal Antibody Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global CD38 Monoclonal Antibody Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas CD38 Monoclonal Antibody Drugs Sales Growth
4.4 APAC CD38 Monoclonal Antibody Drugs Sales Growth
4.5 Europe CD38 Monoclonal Antibody Drugs Sales Growth
4.6 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Growth
5 AMERICAS
5.1 Americas CD38 Monoclonal Antibody Drugs Sales by Country
5.1.1 Americas CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023)
5.1.2 Americas CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023)
5.2 Americas CD38 Monoclonal Antibody Drugs Sales by Type
5.3 Americas CD38 Monoclonal Antibody Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD38 Monoclonal Antibody Drugs Sales by Region
6.1.1 APAC CD38 Monoclonal Antibody Drugs Sales by Region (2018-2023)
6.1.2 APAC CD38 Monoclonal Antibody Drugs Revenue by Region (2018-2023)
6.2 APAC CD38 Monoclonal Antibody Drugs Sales by Type
6.3 APAC CD38 Monoclonal Antibody Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe CD38 Monoclonal Antibody Drugs by Country
7.1.1 Europe CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023)
7.1.2 Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023)
7.2 Europe CD38 Monoclonal Antibody Drugs Sales by Type
7.3 Europe CD38 Monoclonal Antibody Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CD38 Monoclonal Antibody Drugs by Country
8.1.1 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type
8.3 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CD38 Monoclonal Antibody Drugs
10.3 Manufacturing Process Analysis of CD38 Monoclonal Antibody Drugs
10.4 Industry Chain Structure of CD38 Monoclonal Antibody Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CD38 Monoclonal Antibody Drugs Distributors
11.3 CD38 Monoclonal Antibody Drugs Customer
12 WORLD FORECAST REVIEW FOR CD38 MONOCLONAL ANTIBODY DRUGS BY GEOGRAPHIC REGION
12.1 Global CD38 Monoclonal Antibody Drugs Market Size Forecast by Region
12.1.1 Global CD38 Monoclonal Antibody Drugs Forecast by Region (2024-2029)
12.1.2 Global CD38 Monoclonal Antibody Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CD38 Monoclonal Antibody Drugs Forecast by Type
12.7 Global CD38 Monoclonal Antibody Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Johnson
13.1.1 Johnson Company Information
13.1.2 Johnson CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.1.3 Johnson CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Johnson Main Business Overview
13.1.5 Johnson Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.2.3 Sanofi CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Takeda Pharmaceutical Company
13.3.1 Takeda Pharmaceutical Company Company Information
13.3.2 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.3.3 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Takeda Pharmaceutical Company Main Business Overview
13.3.5 Takeda Pharmaceutical Company Latest Developments
13.4 CASI Pharmaceutical Company
13.4.1 CASI Pharmaceutical Company Company Information
13.4.2 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.4.3 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 CASI Pharmaceutical Company Main Business Overview
13.4.5 CASI Pharmaceutical Company Latest Developments
13.5 Mab Biopharma
13.5.1 Mab Biopharma Company Information
13.5.2 Mab Biopharma CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
13.5.3 Mab Biopharma CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Mab Biopharma Main Business Overview
13.5.5 Mab Biopharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. CD38 Monoclonal Antibody Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. CD38 Monoclonal Antibody Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Daretuzumab
Table 4. Major Players of Isartuximab
Table 5. Major Players of Engineered Toxin Body
Table 6. Global CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 7. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Table 8. Global CD38 Monoclonal Antibody Drugs Revenue by Type (2018-2023) & ($ million)
Table 9. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2018-2023)
Table 10. Global CD38 Monoclonal Antibody Drugs Sale Price by Type (2018-2023) & (US$/g)
Table 11. Global CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 12. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Table 13. Global CD38 Monoclonal Antibody Drugs Revenue by Application (2018-2023)
Table 14. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application (2018-2023)
Table 15. Global CD38 Monoclonal Antibody Drugs Sale Price by Application (2018-2023) & (US$/g)
Table 16. Global CD38 Monoclonal Antibody Drugs Sales by Company (2018-2023) & (KG)
Table 17. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company (2018-2023)
Table 18. Global CD38 Monoclonal Antibody Drugs Revenue by Company (2018-2023) ($ Millions)
Table 19. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company (2018-2023)
Table 20. Global CD38 Monoclonal Antibody Drugs Sale Price by Company (2018-2023) & (US$/g)
Table 21. Key Manufacturers CD38 Monoclonal Antibody Drugs Producing Area Distribution and Sales Area
Table 22. Players CD38 Monoclonal Antibody Drugs Products Offered
Table 23. CD38 Monoclonal Antibody Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global CD38 Monoclonal Antibody Drugs Sales by Geographic Region (2018-2023) & (KG)
Table 27. Global CD38 Monoclonal Antibody Drugs Sales Market Share Geographic Region (2018-2023)
Table 28. Global CD38 Monoclonal Antibody Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global CD38 Monoclonal Antibody Drugs Sales by Country/Region (2018-2023) & (KG)
Table 31. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Country/Region (2018-2023)
Table 32. Global CD38 Monoclonal Antibody Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023) & (KG)
Table 35. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2018-2023)
Table 36. Americas CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 38. Americas CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 39. Americas CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 40. APAC CD38 Monoclonal Antibody Drugs Sales by Region (2018-2023) & (KG)
Table 41. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2018-2023)
Table 42. APAC CD38 Monoclonal Antibody Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2018-2023)
Table 44. APAC CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 45. APAC CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 46. Europe CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023) & (KG)
Table 47. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2018-2023)
Table 48. Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 50. Europe CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 51. Europe CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 52. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023) & (KG)
Table 53. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 57. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 58. Key Market Drivers & Growth Opportunities of CD38 Monoclonal Antibody Drugs
Table 59. Key Market Challenges & Risks of CD38 Monoclonal Antibody Drugs
Table 60. Key Industry Trends of CD38 Monoclonal Antibody Drugs
Table 61. CD38 Monoclonal Antibody Drugs Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. CD38 Monoclonal Antibody Drugs Distributors List
Table 64. CD38 Monoclonal Antibody Drugs Customer List
Table 65. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Region (2024-2029) & (KG)
Table 66. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2024-2029) & (KG)
Table 68. Americas CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC CD38 Monoclonal Antibody Drugs Sales Forecast by Region (2024-2029) & (KG)
Table 70. APAC CD38 Monoclonal Antibody Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2024-2029) & (KG)
Table 72. Europe CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2024-2029) & (KG)
Table 74. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Type (2024-2029) & (KG)
Table 76. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Application (2024-2029) & (KG)
Table 78. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Johnson Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Johnson CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 81. Johnson CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 82. Johnson Main Business
Table 83. Johnson Latest Developments
Table 84. Sanofi Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 86. Sanofi CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Takeda Pharmaceutical Company Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 91. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 92. Takeda Pharmaceutical Company Main Business
Table 93. Takeda Pharmaceutical Company Latest Developments
Table 94. CASI Pharmaceutical Company Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 96. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 97. CASI Pharmaceutical Company Main Business
Table 98. CASI Pharmaceutical Company Latest Developments
Table 99. Mab Biopharma Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Mab Biopharma CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 101. Mab Biopharma CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 102. Mab Biopharma Main Business
Table 103. Mab Biopharma Latest Developments
Table 1. CD38 Monoclonal Antibody Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. CD38 Monoclonal Antibody Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Daretuzumab
Table 4. Major Players of Isartuximab
Table 5. Major Players of Engineered Toxin Body
Table 6. Global CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 7. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Table 8. Global CD38 Monoclonal Antibody Drugs Revenue by Type (2018-2023) & ($ million)
Table 9. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2018-2023)
Table 10. Global CD38 Monoclonal Antibody Drugs Sale Price by Type (2018-2023) & (US$/g)
Table 11. Global CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 12. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Table 13. Global CD38 Monoclonal Antibody Drugs Revenue by Application (2018-2023)
Table 14. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application (2018-2023)
Table 15. Global CD38 Monoclonal Antibody Drugs Sale Price by Application (2018-2023) & (US$/g)
Table 16. Global CD38 Monoclonal Antibody Drugs Sales by Company (2018-2023) & (KG)
Table 17. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company (2018-2023)
Table 18. Global CD38 Monoclonal Antibody Drugs Revenue by Company (2018-2023) ($ Millions)
Table 19. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company (2018-2023)
Table 20. Global CD38 Monoclonal Antibody Drugs Sale Price by Company (2018-2023) & (US$/g)
Table 21. Key Manufacturers CD38 Monoclonal Antibody Drugs Producing Area Distribution and Sales Area
Table 22. Players CD38 Monoclonal Antibody Drugs Products Offered
Table 23. CD38 Monoclonal Antibody Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global CD38 Monoclonal Antibody Drugs Sales by Geographic Region (2018-2023) & (KG)
Table 27. Global CD38 Monoclonal Antibody Drugs Sales Market Share Geographic Region (2018-2023)
Table 28. Global CD38 Monoclonal Antibody Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global CD38 Monoclonal Antibody Drugs Sales by Country/Region (2018-2023) & (KG)
Table 31. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Country/Region (2018-2023)
Table 32. Global CD38 Monoclonal Antibody Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023) & (KG)
Table 35. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2018-2023)
Table 36. Americas CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 38. Americas CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 39. Americas CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 40. APAC CD38 Monoclonal Antibody Drugs Sales by Region (2018-2023) & (KG)
Table 41. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2018-2023)
Table 42. APAC CD38 Monoclonal Antibody Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2018-2023)
Table 44. APAC CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 45. APAC CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 46. Europe CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023) & (KG)
Table 47. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2018-2023)
Table 48. Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 50. Europe CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 51. Europe CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 52. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Country (2018-2023) & (KG)
Table 53. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type (2018-2023) & (KG)
Table 57. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application (2018-2023) & (KG)
Table 58. Key Market Drivers & Growth Opportunities of CD38 Monoclonal Antibody Drugs
Table 59. Key Market Challenges & Risks of CD38 Monoclonal Antibody Drugs
Table 60. Key Industry Trends of CD38 Monoclonal Antibody Drugs
Table 61. CD38 Monoclonal Antibody Drugs Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. CD38 Monoclonal Antibody Drugs Distributors List
Table 64. CD38 Monoclonal Antibody Drugs Customer List
Table 65. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Region (2024-2029) & (KG)
Table 66. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2024-2029) & (KG)
Table 68. Americas CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC CD38 Monoclonal Antibody Drugs Sales Forecast by Region (2024-2029) & (KG)
Table 70. APAC CD38 Monoclonal Antibody Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2024-2029) & (KG)
Table 72. Europe CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2024-2029) & (KG)
Table 74. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Type (2024-2029) & (KG)
Table 76. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Application (2024-2029) & (KG)
Table 78. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Johnson Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Johnson CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 81. Johnson CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 82. Johnson Main Business
Table 83. Johnson Latest Developments
Table 84. Sanofi Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 86. Sanofi CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Takeda Pharmaceutical Company Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 91. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 92. Takeda Pharmaceutical Company Main Business
Table 93. Takeda Pharmaceutical Company Latest Developments
Table 94. CASI Pharmaceutical Company Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 96. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 97. CASI Pharmaceutical Company Main Business
Table 98. CASI Pharmaceutical Company Latest Developments
Table 99. Mab Biopharma Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Mab Biopharma CD38 Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 101. Mab Biopharma CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 102. Mab Biopharma Main Business
Table 103. Mab Biopharma Latest Developments
LIST OF FIGURES
Figure 1. Picture of CD38 Monoclonal Antibody Drugs
Figure 2. CD38 Monoclonal Antibody Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global CD38 Monoclonal Antibody Drugs Sales Growth Rate 2018-2029 (KG)
Figure 7. Global CD38 Monoclonal Antibody Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. CD38 Monoclonal Antibody Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Daretuzumab
Figure 10. Product Picture of Isartuximab
Figure 11. Product Picture of Engineered Toxin Body
Figure 12. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type in 2022
Figure 13. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2018-2023)
Figure 14. CD38 Monoclonal Antibody Drugs Consumed in Multiple Myeloma
Figure 15. Global CD38 Monoclonal Antibody Drugs Market: Multiple Myeloma (2018-2023) & (KG)
Figure 16. CD38 Monoclonal Antibody Drugs Consumed in Diffuse Large B Cell Lymphoma
Figure 17. Global CD38 Monoclonal Antibody Drugs Market: Diffuse Large B Cell Lymphoma (2018-2023) & (KG)
Figure 18. CD38 Monoclonal Antibody Drugs Consumed in Other
Figure 19. Global CD38 Monoclonal Antibody Drugs Market: Other (2018-2023) & (KG)
Figure 20. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2022)
Figure 21. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application in 2022
Figure 22. CD38 Monoclonal Antibody Drugs Sales Market by Company in 2022 (KG)
Figure 23. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company in 2022
Figure 24. CD38 Monoclonal Antibody Drugs Revenue Market by Company in 2022 ($ Million)
Figure 25. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company in 2022
Figure 26. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Geographic Region in 2022
Figure 28. Americas CD38 Monoclonal Antibody Drugs Sales 2018-2023 (KG)
Figure 29. Americas CD38 Monoclonal Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 30. APAC CD38 Monoclonal Antibody Drugs Sales 2018-2023 (KG)
Figure 31. APAC CD38 Monoclonal Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 32. Europe CD38 Monoclonal Antibody Drugs Sales 2018-2023 (KG)
Figure 33. Europe CD38 Monoclonal Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales 2018-2023 (KG)
Figure 35. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 36. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2022
Figure 37. Americas CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2022
Figure 38. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 39. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 40. United States CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Region in 2022
Figure 45. APAC CD38 Monoclonal Antibody Drugs Revenue Market Share by Regions in 2022
Figure 46. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 47. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 48. China CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. India CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2022
Figure 56. Europe CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2022
Figure 57. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 58. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 59. Germany CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 60. France CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2022
Figure 65. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 68. Egypt CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of CD38 Monoclonal Antibody Drugs in 2022
Figure 74. Manufacturing Process Analysis of CD38 Monoclonal Antibody Drugs
Figure 75. Industry Chain Structure of CD38 Monoclonal Antibody Drugs
Figure 76. Channels of Distribution
Figure 77. Global CD38 Monoclonal Antibody Drugs Sales Market Forecast by Region (2024-2029)
Figure 78. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global CD38 Monoclonal Antibody Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global CD38 Monoclonal Antibody Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of CD38 Monoclonal Antibody Drugs
Figure 2. CD38 Monoclonal Antibody Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global CD38 Monoclonal Antibody Drugs Sales Growth Rate 2018-2029 (KG)
Figure 7. Global CD38 Monoclonal Antibody Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. CD38 Monoclonal Antibody Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Daretuzumab
Figure 10. Product Picture of Isartuximab
Figure 11. Product Picture of Engineered Toxin Body
Figure 12. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type in 2022
Figure 13. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2018-2023)
Figure 14. CD38 Monoclonal Antibody Drugs Consumed in Multiple Myeloma
Figure 15. Global CD38 Monoclonal Antibody Drugs Market: Multiple Myeloma (2018-2023) & (KG)
Figure 16. CD38 Monoclonal Antibody Drugs Consumed in Diffuse Large B Cell Lymphoma
Figure 17. Global CD38 Monoclonal Antibody Drugs Market: Diffuse Large B Cell Lymphoma (2018-2023) & (KG)
Figure 18. CD38 Monoclonal Antibody Drugs Consumed in Other
Figure 19. Global CD38 Monoclonal Antibody Drugs Market: Other (2018-2023) & (KG)
Figure 20. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2022)
Figure 21. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application in 2022
Figure 22. CD38 Monoclonal Antibody Drugs Sales Market by Company in 2022 (KG)
Figure 23. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company in 2022
Figure 24. CD38 Monoclonal Antibody Drugs Revenue Market by Company in 2022 ($ Million)
Figure 25. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company in 2022
Figure 26. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Geographic Region in 2022
Figure 28. Americas CD38 Monoclonal Antibody Drugs Sales 2018-2023 (KG)
Figure 29. Americas CD38 Monoclonal Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 30. APAC CD38 Monoclonal Antibody Drugs Sales 2018-2023 (KG)
Figure 31. APAC CD38 Monoclonal Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 32. Europe CD38 Monoclonal Antibody Drugs Sales 2018-2023 (KG)
Figure 33. Europe CD38 Monoclonal Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales 2018-2023 (KG)
Figure 35. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 36. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2022
Figure 37. Americas CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2022
Figure 38. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 39. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 40. United States CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Region in 2022
Figure 45. APAC CD38 Monoclonal Antibody Drugs Revenue Market Share by Regions in 2022
Figure 46. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 47. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 48. China CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. India CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2022
Figure 56. Europe CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2022
Figure 57. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 58. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 59. Germany CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 60. France CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2022
Figure 65. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 68. Egypt CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country CD38 Monoclonal Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of CD38 Monoclonal Antibody Drugs in 2022
Figure 74. Manufacturing Process Analysis of CD38 Monoclonal Antibody Drugs
Figure 75. Industry Chain Structure of CD38 Monoclonal Antibody Drugs
Figure 76. Channels of Distribution
Figure 77. Global CD38 Monoclonal Antibody Drugs Sales Market Forecast by Region (2024-2029)
Figure 78. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global CD38 Monoclonal Antibody Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global CD38 Monoclonal Antibody Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Application (2024-2029)
